325 results on '"Laroni, Alice"'
Search Results
2. SARS-CoV-2 vaccination and multiple sclerosis: a large multicentric study on relapse risk after the third booster dose
3. Cladribine Tablets Mode of Action, Learning from the Pandemic: A Narrative Review
4. Summary of Research: Caregiver Involvement in MS: Duty or Disruption?
5. Caregiver Involvement in MS: Duty or Disruption?
6. Relapsing meningitis and limbic encephalitis in anti-AQP4-Ab-associated neuromyelitis optica spectrum disorder.
7. Impact of Natural Killer (NK) Cells on Immune Reconstitution, and Their Potential as a Biomarker of Disease Activity, in Alemtuzumab-Treated Patients with Relapsing Remitting Multiple Sclerosis: An Observational Study
8. Safety, tolerability, and activity of mesenchymal stem cells versus placebo in multiple sclerosis (MESEMS): a phase 2, randomised, double-blind crossover trial
9. Predictors of Ocrelizumab Effectiveness in Patients with Multiple Sclerosis
10. MRI activity and extended interval of Natalizumab dosing regimen: a multicentre Italian study
11. Mesenchymal Stem/Stromal Cells for Multiple Sclerosis and Other Neurological Diseases
12. Erythropoietin therapy in a case of neonatal anemia after exposure to natalizumab throughout pregnancy
13. Extending the Interval of Natalizumab Dosing: Is Efficacy Preserved?
14. Cardiovascular autonomic individual profile of relapsing-remitting multiple sclerosis patients and risk of extending cardiac monitoring after first dose fingolimod
15. No evidence of disease activity (NEDA-3) and disability improvement after alemtuzumab treatment for multiple sclerosis: a 36-month real-world study
16. Cladribine vs other drugs in MS: Merging randomized trial with real-life data
17. Impact of treatment on cellular immunophenotype in MS: A cross-sectional study
18. A multicentRE observational analysiS of PErsistenCe to Treatment in the new multiple sclerosis era: the RESPECT study
19. MEsenchymal StEm cells for Multiple Sclerosis (MESEMS): a randomized, double blind, cross-over phase I/II clinical trial with autologous mesenchymal stem cells for the therapy of multiple sclerosis
20. CD19+ B cell values predict the increase of anti-SARS CoV2 antibodies in fingolimod-treated and COVID-19-vaccinated patients with multiple sclerosis
21. Aging with multiple sclerosis: Clinical characterization of an elderly population, a cross-sectional study
22. Safety and tolerability of fingolimod in patients with relapsing-remitting multiple sclerosis: results of an open-label clinical trial in Italy
23. Teriflunomide treatment reduces B cells in patients with MS
24. Pregnancy decision-making in women with multiple sclerosis treated with natalizumab: I: Fetal risks
25. Pregnancy decision-making in women with multiple sclerosis treated with natalizumab: II: Maternal risks
26. Vaccinations in patients with multiple sclerosis: a real-world, single-center experience
27. Breakthrough SARS-CoV-2 infections in MS patients on disease-modifying therapies
28. Breakthrough SARS-CoV-2 infections after COVID-19 mRNA vaccination in MS patients on disease modifying therapies during the Delta and the Omicron waves in Italy
29. Assessing association of comorbidities with treatment choice and persistence in MS: A real-life multicenter study
30. Long-term disability progression in primary progressive multiple sclerosis: a 15-year study
31. High or increasing serum NfL is predictive of impending multiple sclerosis relapses
32. sj-docx-1-msj-10.1177_13524585221102918 – Supplemental material for Breakthrough SARS-CoV-2 infections in MS patients on disease-modifying therapies
33. Neuroprotective features of mesenchymal stem cells
34. Mesenchymal stem cells for the treatment of multiple sclerosis and other neurological diseases
35. Impact of Natural Killer (NK) Cells on Immune Reconstitution, and Their Potential as a Biomarker of Disease Activity, in Alemtuzumab-Treated Patients with Relapsing Remitting Multiple Sclerosis: An Observational Study
36. Towards Clinical Application of Mesenchymal Stem Cells for Treatment of Neurological Diseases of the Central Nervous System
37. Role of the innate immune system in the pathogenesis of multiple sclerosis
38. Caregiver Involvement in MS: Duty or Disruption?
39. Safety, tolerability, and activity of mesenchymal stem cells versus placebo in multiple sclerosis (MESEMS): a phase 2, randomised, double-blind crossover trial
40. A real‐world study of alemtuzumab in a cohort of Italian patients
41. Predictors of ocrelizumab effectiveness in patients with multiple sclerosis
42. Effect of SARS-CoV-2 mRNA vaccination in MS patients treated with disease modifying therapies
43. mRNA COVID-19 vaccines do not increase the short-term risk of clinical relapses in multiple sclerosis
44. Disease Progression in Multiple Sclerosis: A Literature Review Exploring Patient Perspectives
45. Safety, tolerability, and activity of mesenchymal stem cells versus placebo in multiple sclerosis (MESEMS):a phase 2, randomised, double-blind crossover trial
46. Ocrelizumab treatment in patients with progressive multiple sclerosis: a single-center real-world experience (2504)
47. Immune Soluble Factors in the Cerebrospinal Fluid of Progressive Multiple Sclerosis Patients Segregate Into Two Groups
48. sj-pdf-1-msj-10.1177_1352458520971817 – Supplemental material for COVID-19 in patients with multiple sclerosis undergoing disease-modifying treatments
49. Multiple sclerosis and autoimmune diseases: epidemiology and HLA-DR association in North-east Italy
50. T-cell trafficking in the central nervous system
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.